Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study

Abstract

Background Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic treatment (antidiabetic oral agents and/or insulin)]. We investigated whether clinical data at varied stages of pregnancy can predict GDM treatment modality. Methods Among a population-based cohort of 30,474 pregnancies with GDM delivered at Kaiser Permanente Northern California in 2007–2017, we selected those in 2007–2016 as the discovery set and 2017 as the temporal/future validation set. Potential predictors were extracted from electronic health records at different timepoints (levels 1–4): (1) 1-year preconception to the last menstrual period, (2) the last menstrual period to GDM diagnosis, (3) at GDM diagnosis, and (4) 1 week after GDM diagnosis. We compared transparent and ensemble machine learning prediction methods, including least absolute shrinkage and selection operator (LASSO) regression and super learner, containing classification and regression tree, LASSO regression, random forest, and extreme gradient boosting algorithms, to predict risks for pharmacologic treatment beyond MNT. Results The super learner using levels 1–4 predictors had higher predictability [tenfold cross-validated C-statistic in discovery/validation set: 0.934 (95% CI: 0.931–0.936)/0.815 (0.800–0.829)], compared to levels 1, 1–2, and 1–3 (discovery/validation set C-statistic: 0.683–0.869/0.634–0.754). A simpler, more interpretable model, including timing of GDM diagnosis, diagnostic fasting glucose value, and the status and frequency of glycemic control at fasting during one-week post diagnosis, was developed using tenfold cross-validated logistic regression based on super learner-selected predictors. This model compared to the super learner had only a modest reduction in predictability [discovery/validation set C-statistic: 0.825 (0.820–0.830)/0.798 (95% CI: 0.783–0.813)]. Conclusions Clinical data demonstrated reasonably high predictability for GDM treatment modality at the time of GDM diagnosis and high predictability at 1-week post GDM diagnosis. These population-based, clinically oriented models may support algorithm-based risk-stratification for treatment modality, inform timely treatment, and catalyze more effective management of GDM.

Precision gestational diabetes treatment: a systematic review and meta-analyses

“…Notably, many of the identified precision markers are routinely measured in clinical practice and so could be incorporated into prediction models of need for pharmacological treatment 70 , 71 . By identifying those who require escalation of pharmacological therapy earlier, better allocation of resources can be achieved.…”

Artificial intelligence in cardiovascular prevention: new ways will open new doors

“…In this field, the use of artificial intelligence has been tested to enhance the prediction and diagnosis of significant complications of diabetes leading to adverse cardiovascular events 20 . This is of particular interest in the field of gestational diabetes and recent research has identified the possibility of using a dedicated machine learning approach to improve its prediction 21 …”

“…20 This is of particular interest in the field of gestational diabetes and recent research has identified the possibility of using a dedicated machine learning approach to improve its prediction. 21 In the management of dyslipidaemia, different potential applications of artificial intelligence have been tested so far, starting from the diagnosis to the management and prognosis related to the disease. Recently machine learning modelling has been applied to big datasets to obtain more accurate predictive models for incident dyslipidaemia, taking into account monogenic or polygenic variants.…”

Historical and statistical aspects of risk groups analysis and testing in the context of gestational diabetes mellitus

“…When deciding on the recommendations for universal or selective GDM screening it is necessary to define the population that should be screened, the recommended screening methods and their timing, as well as the treatment modalities and the follow-up [7].…”